Finanzen von Tvardi Therapeutics Inc (TVRD)TVRDTvardi Therapeutics Inc

Tvardi Therapeutics, Inc. (TVRD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Other revenue , accounting for 51.5% of total sales, equivalent to $1.32M. Other significant revenue streams include Collaborative revenue and Clinical compound revenue. Understanding this composition is critical for investors evaluating how TVRD navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Tvardi Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -126.19%, provide a clear picture of how effectively TVRD converts its operational activities into shareholder value.

In the context of the broader market, TVRD competes directly with industry leaders such as ENLV and EVAX. With a market capitalization of $25.08M, it holds a leading position in the sector. When comparing efficiency, TVRD's gross margin of N/A stands against ENLV's N/A and EVAX's N/A. Such benchmarking helps identify whether Tvardi Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company has reported a total revenue of $2,569,000 for Q1 2025 but has consistently negative net income, with Q2 2026 showing a loss of -$6,457,000. The gross margin for Q1 2025 was 100%, but subsequent quarters have not generated revenue, indicating volatility in financial performance.